Patents by Inventor Qing-Song Liu

Qing-Song Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250129329
    Abstract: A culture medium for hepatoma organoid culture, comprising an MST1/2 kinase inhibitor, at least one cell culture additive selected from N2 and B27, a hepatocyte growth factor, an ITS cell culture additive, Y27632, dexamethasone, Neuregulin-1, insulin, an epidermal cell growth factor, GlutaMAX, and non-essential amino acids. The application further relates to a hepatoma organoid culture method and an application thereof. By using the culture medium for hepatoma organoid, effective and rapid expansion of the hepatoma organoid can be achieved, and the organoid obtained by such expansion maintains the pathological characteristics of a patient, improves the culture success rate and the expansion rate of the hepatoma organoid, and provides a research basis for individualized treatment of the patient.
    Type: Application
    Filed: September 16, 2021
    Publication date: April 24, 2025
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Qing Song LIU, Wen Liang Wang, Tao HUANG, Cheng CHEN
  • Publication number: 20250101378
    Abstract: A culture medium for culturing mammary epithelial cells, which medium contains ?-estradiol, insulin-like growth factor 1, basic fibroblast growth factor, tumor necrosis factor-?, and optionally fibroblast growth factor 10. A method for culturing mammary epithelial cells using the culture medium, and a method and the use of cells obtained using the culture method in evaluating or screening the efficacy of a drug.
    Type: Application
    Filed: February 9, 2022
    Publication date: March 27, 2025
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Qing Song LIU, Fei Yang LIU, Jie ZHANG, Cheng CHEN, Wen Chao WANG
  • Publication number: 20240344035
    Abstract: Provided are a culture medium and a culture method for human primary acute myeloid leukemia cells. The culture medium for human primary acute myeloid leukemia cells contains a glutamine additive, non-essential amino acids, human interleukin-6, human interleukin-7, human interleukin-3, recombinant human FLT3 Ligand, a recombinant human macrophage colony stimulating factor and a human stem cell factor. Acute myeloid leukemia cells can be cultured with higher amplification efficiency and longer in-vitro culture time by using the culture medium and culture method. Also provided are human primary acute myeloid leukemia cells cultured in vitro by using the culture medium, and the use thereof for curative effect evaluation and screening of drugs.
    Type: Application
    Filed: August 31, 2021
    Publication date: October 17, 2024
    Inventors: Qing Song LIU, Yu Ying HE, Cheng CHEN, Tao HUANG, Tao REN, Wen Chao WANG, Li WANG
  • Patent number: 12115152
    Abstract: The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 15, 2024
    Assignee: TARAPEUTICS SCIENCE INC.
    Inventors: Qing Song Liu, Jing Liu, Xi Xiang Li, Ao Li Wang, Zi Ping Qi, Qing Wang Liu, Zong Ru Jiang, Feng Ming Zou, Wen Chao Wang, Chen Hu, Cheng Chen, Li Wang
  • Publication number: 20230212523
    Abstract: Provide are a primay cell culture medium that contains an MST1/2 kinase inhibitor and is used for culturing laryngeal cancer epithelial cells, and a culture method using the primary cell culture medium. In the culture method, the primay cell culture medium is used to culture primary cells on a clulture vessel plated with irradiated trophoblasts, so that the primay cells proliferate rapidly. A cell model obtained by the primary cell culture medium and the primay cell culture method can be used for the efficacy evaluation and screening of drugs.
    Type: Application
    Filed: July 22, 2020
    Publication date: July 6, 2023
    Applicant: CAS (Hefei) Institute of Technology Innovation
    Inventors: Qing Song LIU, Jie HU, Tao REN
  • Publication number: 20220288064
    Abstract: Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFR? and/or PDGFR? kinase activity.
    Type: Application
    Filed: August 14, 2020
    Publication date: September 15, 2022
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qing Song LIU, Jing LIU, Xi Xiang LI, Ao Li WANG, Feng Ming ZOU, Cheng CHEN, Qing Wang LIU, Juan LIU, Jiang Yan CAO, Wen Liang WANG, Shuang QI, Wen Chao WANG, Bei Lei WANG, Li WANG
  • Publication number: 20220143001
    Abstract: The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.
    Type: Application
    Filed: March 7, 2019
    Publication date: May 12, 2022
    Applicant: TARAPEUTICS SCIENCE INC.
    Inventors: Qing Song LIU, Jing LIU, Xi Xiang LI, Ao Li WANG, Zi Ping QI, Qing Wang LIU, Zong Ru JIANG, Feng Ming ZOU, Wen Chao WANG, Chen HU, Cheng CHEN, Li WANG
  • Patent number: D598384
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 18, 2009
    Assignee: Hon Hai Precision Ind. Co., Ltd.
    Inventors: Qing-Song Liu, Xing-Hai Xiang, Lun-Song Hu, Zi-Qiang Zhu
  • Patent number: D598385
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 18, 2009
    Assignee: Hon Hai Precision Ind. Co., Ltd.
    Inventors: Qing-Song Liu, Xing-Hai Xiang, Lun-Song Hu, Zi-Qiang Zhu
  • Patent number: D598386
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 18, 2009
    Assignee: Hon Hai Precision Ind. Co., Ltd.
    Inventors: Qing-Song Liu, Xing-Hai Xiang, Lun-Song Hu, Zi-Qiang Zhu